Associate Professor, Otorhinolaryngology/Head and Neck Surgery, Perelman School of Medicine
Oncology
Dr. Marcia S. Brose, MD
|
|
Give Review
Marcia Brose is an expert in the field of Oncology. She went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University has a rank of 18 in research and a 49 in primary care She received 1 awards: "CMS Meaningful Use Stage 1 Certification". Marcia Brose is a published doctor and has 38 publications published. The lastest was: 'STK11 Mutation Identified in Thyroid Carcinoma.' She is registered with Medicare and accepts Medicare payments.
Publications
- STK11 Mutation Identified in Thyroid Carcinoma.
- Lenvatinib versus placebo in radioiodine-refractory thyroid Cancer.
- BRAF Mutation and Thyroid Cancer Recurrence.
- A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer.
- Second-line treatment for advanced thyroid Cancer: an indication in need of randomized clinical trials.
- Physician and Stakeholder Perceptions of Conflict of Interest Policies in Oncology.
- Clinical Cancer advances 2012: annual report on progress against Cancer from the american society of clinical oncology.
- Rap1GAP inhibits cytoskeletal remodeling and motility in thyroid Cancer cells.
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study.
- In search of a real "targeted" therapy for thyroid Cancer.
- Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with local...
- Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion.
- Activating mutations in BRAF characterize a spectrum of pediatric low-grade Gliomas.
- Targeting vascular endothelial growth factor receptor in thyroid Cancer: the intracellular and extracellular implications.
- Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.
- SOX2 is an amplified lineage-survival oncogene in lung and Esophageal squamous cell carcinomas.
- Thyroid Cancer update: dramatic changes in the treatment of a rare disease.
- Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin Cancer tissues.
- Loss of Rap1GAP in papillary thyroid Cancer.
- Phase II trial of sorafenib in advanced thyroid Cancer.
- A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
- Downregulation of Rap1GAP contributes to Ras transformation.
- Application of a BRAF pyrosequencing assay for mutation detection and copy number Analysis in malignant melanoma.
- A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and Lung squamous cell carcinoma.
- Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization.
- Her-2 targeted therapy: beyond breast Cancer and trastuzumab.
- Constitutive mitogen-activated protein kinase activation in Melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
- BRAF and RAS mutations in human lung Cancer and melanoma.
- Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
- A comparative study of EGFR mutation screening methods in non-small cell carcinoma of Lung.
- Lack of BRAF mutations in hyalinizing trabecular Neoplasm.
- Targeted inhibition of CD133+ cells in oral Cancer cell lines.
- The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK.
- Germline CHEK2*1100delC mutations in breast Cancer patients with multiple primary Cancers.
- Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.
- Absence of BRAF mutations in UV-protected mucosal Melanomas.
- Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response.
Schools
Joan Sanford I Weill Medical College Of Cornell University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Pennsylvania Health System -
Weill Cornell Medical College of Cornell University
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center
Drug Facts
| NPI NUMBER | 1316975451 | |
| NPPES Provider LastName | BROSE | |
| NPPES Provider FirstName | MARCIA | |
| NPPES Provider ZIPCode | 191044206 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 179.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316975451 |
| Last Name Of The Provider | BROSE |
| First Name Of The Provider | MARCIA |
| View All |
Similar Doctors
|
|
Lindsay R. Wilde
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Seyfettin O. Alpdogan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen J. Bagley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason Palopoli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Angela Jain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dale Bryansmith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juhi Mittal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bijoyesh Mookerjee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sally D. Lane, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Hoxie, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joshua M. Bauml, MD
This Doctor is OpenDoctor Recommended.
|